🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. Chinese Medicine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Mountain Sickness (AMS)

    phase 2 small molecule active

    1 trial

  2. Chinese Medicine Oral Rinse Formula-I (CMORF-I)

    Chinese University of Hong Kong

    Head and Neck Neoplasms

    phase 2 small molecule active

    1 trial

  3. Cholecalciferol

    Hospital Authority, Hong Kong

    Hematologic Neoplasms

    phase 2 small molecule active

    1 trial

  4. Comirnaty JN.1 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, LVT-001

    Tour Hekla

    Healthy volunteers

    phase 2 small molecule active

    1 trial

  5. DEGARELIX ACETATE, ENZALUTAMIDE, DEGARELIX, ENZALUTAMIDE, DAROLUTAMIDE, RELUGOLIX, -, ENZALUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, Pluvicto 1 000 MBq/mL solution for injection/infusion, APALUTAMIDE

    Novartis Pharmaceuticals

    PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)

    phase 2 small molecule active

    1 trial

  6. DMTs + taurine

    The First People's Hospital of Lianyungang

    Multiple Sclerosis (MS) Relapsing Remitting

    phase 2 small molecule active

    1 trial

  7. DOR/ISL

    Merck KGaA, Darmstadt, Germany

    HIV-1 Infection

    phase 2 small molecule completed

    1 trial

  8. Dacogen 50 mg powder for concentrate for solution for infusion., Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets

    Fondazione Telethon ETS

    Acute Myeloid Leukemia secondary to myeloproliferative neoplasms

    phase 2 small molecule active

    1 trial

  9. Daptomycin for Injection

    Merck KGaA, Darmstadt, Germany

    Bacteremia

    phase 2 small molecule completed

    1 trial

  10. Darinaparsin

    Alaunos Therapeutics

    Hematologic Neoplasms

    phase 2 small molecule completed

    1 trial

  11. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  12. Dazostinag

    Takeda

    Solid Neoplasms

    phase 2 small molecule completed

    1 trial

  13. Diphenhydramine Hydrochloride Tablets 50 mg, Paracetamol 500mg Tablets, Ocrevus 300 mg concentrate for solution for infusion, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis (RRMS)

    phase 2 small molecule active

    1 trial

  14. Docetaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Prostatic Neoplasms

    phase 2 small molecule completed

    1 trial

  15. Docetaxel

    Merck KGaA, Darmstadt, Germany

    Castration-Resistant Prostatic Cancer

    phase 2 small molecule active

    1 trial

  16. Docetaxel + Sunitinib

    Samsung Bioepis NL B.V.

    Advanced Gastric Cancer

    phase 2 small molecule completed

    1 trial

  17. Doravirine

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV) Infection

    phase 2 small molecule active

    1 trial

  18. EMB-01

    Shanghai University of Traditional Chinese Medicine

    Neoplasms

    phase 2 small molecule active

    1 trial

  19. Efinopegdutide

    Merck KGaA, Darmstadt, Germany

    Non-alcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  20. Efinopegdutide 20 mg/mL

    Merck KGaA, Darmstadt, Germany

    Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  21. Enasidenib

    Agios Netherlands B.V.

    Hematologic Neoplasms

    phase 2 small molecule completed

    1 trial

  22. Endostar

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Neoplasms

    phase 2 small molecule active

    2 trials

  23. Enpatoran Placebo, Enpatoran

    Merck Sharp and Dohme

    Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

    phase 2 small molecule active

    1 trial

  24. Enpatoran placebo, Enpatoran, Enpatoran

    Merck Sharp and Dohme

    Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources